Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02141542 |
| Title | Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | F. Stephen Hodi, MD |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | United States | Details | |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | United States | Details |